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inhibition of mineralization that are removed by TRAP but 
not by BALP. In conclusion, our data indicate that both 
BALP and TRAP can alleviate the inhibitory effect of OPN 
on mineralization, suggesting a potential role for TRAP in 
skeletal mineralization. Further studies are warranted to 
explore the possible physiological relevance of TRAP in 
bone mineralization.
Keywords Bone · Dephosphorylation · Hydroxyapatite · 
Inorganic pyrophosphate · Mineralization · Osteopontin
Introduction
Skeletal remodeling and maintenance is an ongoing pro-
cess with continuous resorption of bone by osteoclasts and 
formation of new bone by osteoblasts. Bone tissue is made 
of collagen fibers that form a scaffold where calcium and 
phosphate, mainly in the form of crystalline hydroxyapatite 
(HA), are deposited [1]. Mineralization is initiated by the 
accumulation of calcium and inorganic phosphate, followed 
by crystal growth [2, 3]. To obtain a normal mineral depo-
sition rate during bone remodeling, the mineralization pro-
cess is controlled by several molecules that either inhibit or 
promote the growth of HA crystals [4, 5].
Osteopontin (OPN), an important regulator of HA crys-
tal formation and growth, is a multifunctional, highly phos-
phorylated protein expressed at high levels in mineralizing 
tissue such as bones and teeth, but also in some soft tis-
sues and body fluids [4, 6–8]. OPN belongs to the small 
integrin-binding ligand N-linked glycoprotein (SIBLING) 
family and is a characteristic intrinsically disordered pro-
tein with structures that are highly flexible [4, 9]. This flex-
ibility enables OPN to rapidly interact with proteins, e.g., 
collagen, as well as hydroxyapatite crystals [10]. Different 
Abstract Phosphorylated osteopontin (OPN) inhibits 
hydroxyapatite crystal formation and growth, and bone 
alkaline phosphatase (BALP) promotes extracellular min-
eralization via the release of inorganic phosphate from the 
mineralization inhibitor inorganic pyrophosphate (PPi). 
Tartrate-resistant acid phosphatase (TRAP), produced by 
osteoclasts, osteoblasts, and osteocytes, exhibits potent 
phosphatase activity towards OPN; however, its potential 
capacity as a regulator of mineralization has not previously 
been addressed. We compared the efficiency of BALP and 
TRAP towards the endogenous substrates for BALP, i.e., 
PPi and pyridoxal 5′-phosphate (PLP), and their impact 
on mineralization in vitro via dephosphorylation of bovine 
milk OPN. TRAP showed higher phosphatase activity 
towards phosphorylated OPN and PPi compared to BALP, 
whereas the activity of TRAP and BALP towards PLP 
was comparable. Bovine milk OPN could be completely 
dephosphorylated by TRAP, liberating all its 28 phos-
phates, whereas BALP dephosphorylated at most 10 phos-
phates. OPN, dephosphorylated by either BALP or TRAP, 
showed a partially or completely attenuated phosphoryla-
tion-dependent inhibitory capacity, respectively, compared 
to native OPN on the formation of mineralized nodules. 
Thus, there are phosphorylations in OPN important for 
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posttranslational modifications such as glycosylation, sulfa-
tion, transglutamination, and phosphorylation influence the 
functional properties of OPN [5, 7, 11]. The secreted Golgi 
casein kinase Fam20C is highly expressed in mineralized 
tissues and appears to be the enzyme regulating HA forma-
tion by phosphorylation of SIBLING proteins. Mutations in 
Fam20C cause an osteosclerotic bone dysplasia in humans 
known as Raine syndrome [12]. The number of phospho-
rylations varies between OPN isolated from different spe-
cies and sources. The reason for the occurrence of different 
degrees of phosphorylation is not fully understood but may 
be related to the different actions of phosphatases on OPN. 
Highly phosphorylated OPN forms the so-called calcium 
phosphate nanoclusters from amorphous calcium phos-
phate precipitates, which is of physiological importance 
since this delays HA crystallization [13]. Phosphorylation 
and dephosphorylation of OPN appear to control several of 
its biological functions, such as cell adhesion and migra-
tion [14]. Milk OPN has 28–36 phosphorylations and OPN 
isolated from bone has 12–13 phosphorylations on average 
[7, 11, 15, 16], a difference possibly related to the action 
of extracellular phosphatases such as bone alkaline phos-
phatase (BALP) and tartrate-resistant acid phosphatase 
(TRAP).
TRAP, also referred to as type 5 acid phosphatase/AcP 5, 
is highly expressed in osteoclasts [17] but is also expressed 
in osteoblasts and osteocytes [18, 19]. TRAP is synthe-
sized as a monomer with low enzyme activity; however, the 
monomer (TRAP 5a) can be converted into a dimer (TRAP 
5b) with high enzymatic activity by posttranslational pro-
teolytic processing [20–22]. TRAP 5b exerts phosphatase 
activity towards OPN and bone sialoprotein [23]; however, 
its potential capacity as a regulator of mineralization has 
not previously been addressed.
Alkaline phosphatase (ALP) is a glycoprotein and func-
tions as an ectoenzyme attached to the outer surface of 
cells and matrix vesicles. In humans, there are four genes 
encoding the ALP isozymes, i.e., intestinal ALP (IALP), 
placental ALP, germ cell ALP, and tissue-nonspecific 
ALP (TNALP) expressed in bone (as BALP), liver, and 
kidney [24]. Studies of hypophosphatasia, a rare inborn-
error-of-metabolism, caused by missense mutations within 
the TNALP gene (ALPL), have provided evidence for an 
important role for ALP in the development and mineraliza-
tion of bone [25]. Hypophosphatasia in TNALP knockout 
mice results in increased inorganic pyrophosphate (PPi) 
concentrations and a concomitant increase in OPN phos-
phorylation levels; the combined effect of these molecules 
leads to hypomineralization [26].
A model to explain the differential roles of the two phos-
phatases BALP and TRAP is missing and their possible 
functional interplay remains to be explored. In this study, 
we hypothesized that BALP and TRAP might substitute 
for each other as regulators of mineralization. The kinetic 
properties of TRAP towards the known endogenous sub-
strates of BALP, i.e., PPi and pyridoxal 5′-phosphate (PLP) 
[25, 27], were investigated in order to explore the possible 
relevance of TRAP in skeletal mineralization. Furthermore, 
it was also investigated how BALP and TRAP can act as 




All reagents were obtained from Sigma-Aldrich (St. Louis, 
MO, USA) if not stated otherwise. BALP, extracted from 
human bone tissue, was obtained from Calzyme Labora-
tories Inc. (San Luis Obispo, CA, USA; Cat#: 124A0001) 
and IALP from bovine intestinal mucosa (Sigma-Aldrich; 
Cat#: A2356). Purification of recombinant human TRAP 
5a from concentrated Baculovirus-infected Spodoptera fru-
giperda (Sf9) insect cell culture supernatant (obtained from 
GenScript USA Inc., Piscataway, NJ, USA) was performed 
according to a previously published protocol [28]. For 
proteolytic cleavage of TRAP 5a to enzymatically active 
TRAP 5b, human liver cathepsin L (Merck Millipore, 
Darmstadt, Germany) was used according to Krumpel et al. 
[28]. Bovine milk OPN was purified according to Bayless 
et al. [29] as modified by Ljusberg et al. [20] In brief, OPN 
was purified from 1 L of raw bovine milk, after the addi-
tion of a protease inhibitor cocktail (Roche Diagnostics 
Scandinavia AB, Bromma, Sweden; Cat#:1697498), using 
one DEAE Sepharose Fast Flow column (GE Healthcare 
Bio-Sciences AB, Uppsala, Sweden; Cat#:17-0709-01) 
and two consecutive Phenyl Sepharose Fast Flow columns 
(GE Healthcare Bio-Sciences AB; Cat#:17-0973-05). The 
identity and purity of the isolated OPN were confirmed 
by SDS-PAGE with silver staining and by amino-terminal 
sequence analysis, and the concentration was determined 
by total amino acid analysis.
Determination of Kinetic Properties for BALP 
and TRAP
Kinetic properties were evaluated for both BALP and 
TRAP 5b using the endogenous substrates for BALP, 
i.e., PPi and PLP, as well as the synthetic substrate 
p-nitrophenylphosphate (pNPP). The kinetic properties 
for TRAP 5b were determined in a buffer with a final 
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concentration of 0.1 M sodium acetate at pH 5.8, 0.15 M 
KCl, 0.1% (v/v) Triton X-100, 10 mM disodium tartrate, 
1 mM ascorbic acid, and 0.1 mM Fe(NH4)2(SO4) (TRAP 
buffer). The kinetic measurements of BALP were car-
ried out in a buffer with a final concentration of 0.2 mM 
 (NH4)2CO3 at pH 8.5, 2 mM  MgCl2, 40 µM zinc acetate, 
and 10 µg/mL E-64 (ALP buffer). TRAP 5b was diluted 
in TRAP buffer to a final concentration of 0.03  ng/µL 
for the measurements with pNPP and PPi, and 0.3  ng/
µL for PLP. BALP was diluted in ALP buffer to a final 
concentration of 0.04  µg/µL for all three substrates. All 
measurements were carried out in 96-well plates and 
incubated at 37 °C for 30  min. For the kinetic measure-
ments, 25 µL of the substrate was added to the final con-
centrations of 0.05  mM to 10  mM together with 25  µL 
TRAP 5b or BALP solution and 50 µL buffer (TRAP or 
ALP buffer). After 30 min, 50 µL stop solution was added 
to each sample, 0.5 M NaOH for the pNPP reaction and 
0.2 M  Na2MoO4 for PPi and PLP. For pNPP, the amount 
of formed p-nitrophenol was measured by absorbance at 
405 nm, and for PPi and PLP the amount of liberated free 
phosphate was determined using the Biomol Green Rea-
gent (Enzo Life Sciences Inc., Farmingdale, NY, USA).
The kinetic parameters, maximum reaction velocity 
(Vmax), and the Michaelis constant (Km) were determined 
from a Lineweaver–Burk plot where the substrate concen-
tration was plotted against the specific enzyme activity.
Dephosphorylation of OPN by BALP, IALP, and TRAP
For time curve analyses, the enzyme activity needed for 
maximal dephosphorylation of 10  µg bovine milk OPN, 
after 24-h incubation at 37 °C, was chosen for each phos-
phatase. PNPP equivalents corresponding to 5 mU TRAP 
5b, 20 mU BALP, and 20 mU IALP were incubated with 
10 µg bovine milk OPN in siliconized Eppendorf tubes. 
Dephosphorylation with TRAP was carried out in a 
buffer containing 0.1 M sodium acetate at pH 5.0, 0.15 M 
KCl, 10 mM disodium tartrate, 1 mM ascorbic acid, and 
0.1  mM Fe(NH4)2(SO4), and stopped at different time 
points, 0–24  h, with 10  mM  Na2MoO4. Dephosphoryla-
tion with BALP and IALP was performed in a buffer con-
taining 200 mM  (NH4)2CO3 at pH 8.5, 2 mM  MgCl2, and 
40 µM zinc acetate, and stopped at different time points 
with 20 mM EDTA. Liberated phosphate was determined 
at each time point by the addition of 100 µL of Biomol 
Green Reagent to 20  µL dephosphorylated OPN and 
incubated for 20 min at room temperature.
Dephosphorylation of OPN was also investigated 
with different quantities of TRAP 5b (0.5, 1.25, 2.5, and 
5 mU), and for BALP and IALP (5, 10, 20, and 40 mU). 
The amount of liberated free phosphate was measured 
with the Biomol Green Reagent after incubation for 24 h.
In Vitro Mineralization
Human osteoblast-like SaOS-2 cells (ATCC, American 
Type Culture Collection, Manassas, VA, USA) were grown 
in 96-well black-walled plates in Dulbecco’s modified 
Eagle’s medium—low glucose, supplemented with 1% fetal 
calf serum, 1% penicillin/streptomycin, and 40 U/mL nys-
tatin, at 37 °C with 95% humidity and 5%  CO2.
Mineralization was initiated 24  h after plating out the 
cells. The medium was replaced with a fresh medium sup-
plemented with 2  mM β-glycerophosphate and 50  µg/
mL ascorbic acid in order to initiate mineralization. Fully 
phosphorylated OPN and partially dephosphorylated OPN 
(by BALP or TRAP) were added to a final concentration 
of 0.1 µg/mL. Cells were cultured for 5 days after the ini-
tiation of mineralization and the medium was changed on 
days 2 and 4. The amount of mineral was quantified using 
the OsteoImage Mineralization Assay (Lonza Walkersville, 
Inc., Walkersville, MD, USA), which specifically binds to 
HA nodules. This assay is, unlike typical histochemical 
methods such as von Kossa and Alizarin Red staining, HA-
specific [30, 31]. The OsteoImage Mineralization Assay is 
an in vitro assay that can quantitate bone cell mineraliza-
tion and is based on the specific binding of the fluorescent 
OsteoImage staining reagent to the HA portion of the bone-
like nodules deposited by cells. The medium was removed 
after 5 days and the cells were fixed with 99% ethanol and 
incubated with the fluorescent OsteoImage reagent. Fluo-
rescence was determined using a Fluoroskan Ascent FL flu-
orescent microplate reader (Thermo Fisher Scientific, Van-
taa, Finland) with excitation/emission set at 485/538  nm. 
The measured fluorescence is proportional to the amount of 
HA present in the culture.
Images of mineralizing cells were captured with a 
10× objective (NA 0.3) on a Zeiss Axio Observer Z1 
with an AxioCam MRm camera (Carl Zeiss MicroImag-
ing, Thornwood, NY, USA) and excitation/emission set at 
485/538 nm. Images of the cells grown were captured: (i) 
without β-glycerophosphate and ascorbic acid; (ii) with 
2 mM β-glycerophosphate and 50 µg/mL ascorbic acid; (iii) 
and with 2  mM β-glycerophosphate, 50  µg/mL ascorbic 
acid, and OPN (fully phosphorylated).
Statistical Analysis
Data were analyzed using the Excel software (Micro-
soft, Redmond, WA, USA). Results are presented as 
mean ± standard deviation (SD). Statistical analyses were 
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performed using unpaired two-tailed Student’s t test for 
comparisons between two groups, and ANOVA was used 
to test for differences involving more than two groups. For 
all statistical tests, a difference was considered significant 
at P < 0.05.
Results
Kinetic Properties for BALP and TRAP
Both BALP and TRAP 5b displayed catalytic activity for 
the three substrates PPi, PLP, and pNPP (Table  1). The 
enzymatic activities at their respective pH optima (i.e., 
BALP, pH 8.5; TRAP 5b, pH 5.8) were significantly higher 
for TRAP in comparison with BALP for all substrates, but 
were particularly pronounced for pNPP and PPi. No signifi-
cant differences in Km for the different substrates for BALP 
and TRAP were noted. The Vmax values were 4300-fold and 
730-fold higher for pNPP and PPi, respectively, for TRAP 
in comparison with BALP. For the substrate PLP, Vmax was 
fourfold higher for TRAP in comparison with BALP.
Table 1  Kinetic properties for the endogenous substrates (for 
BALP), PPi and PLP, and the synthetic substrate pNPP
Results are expressed as mean ± SD of three independent experiments
* P < 0.05, ** P < 0.005, in comparison with TRAP
TRAP BALP
Vmax (mU/mg)
 PPi 22,000 ± 2160 30 ± 13**
 PLP 390 ± 7 90 ± 16*
 pNPP 774,000 ± 160,000 180 ± 9*
Km (mM)
 PPi 1.49 ± 0.10 2.45 ± 1.38
 PLP 0.34 ± 0.28 0.12 ± 0.04
 pNPP 3.00 ± 1.60 0.31 ± 0.01
Fig. 1  Dephosphorylation of OPN by TRAP, BALP, and IALP. OPN 
was completely dephosphorylated (28 free phosphates liberated) after 
24-h incubation with 5  mU of TRAP (filled triangle). During the 
same time period, 20 mU of BALP (filled square) cleaved off 10 free 
phosphates and 20  mU IALP (open square) liberated 20 free phos-
phates from OPN. All experiments were run in triplicate. Statistical 
comparisons were made between TRAP, BALP, and IALP at each 
time point (NS not significant)
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Dephosphorylation of OPN by BALP and TRAP
OPN purified from bovine milk contains 28 phosphoryla-
tions on 27 serine residues and 1 threonine residue [16]. 
When treated with 5  mU TRAP, OPN was completely 
dephosphorylated after 24  h, whereas 20  mU BALP 
dephosphorylated OPN only partially with ten phos-
phates being removed (36%) (Fig.  1). IALP is often used 
to dephosphorylate OPN in experimental studies [32]; 
however, after incubation with 20 mU IALP, only 20 phos-
phates (71%) were removed after 24 h (Fig. 1). Raising the 
amounts of BALP and IALP to 40  mU did not increase 
the amount of liberated free phosphate from OPN at 24 h 
(Fig. 2).
Comparison of the dephosphorylation rates of TRAP, 
BALP, and IALP demonstrated that TRAP can liberate 
3.9 free phosphates per OPN molecule per hour and mU, 
whereas BALP and IALP liberate 0.5 and 1.3 free phos-
phates, respectively (Fig. 3).
In Vitro Mineralization
In the mineralization model, the accumulation of HA 
deposits from osteoblast-like SaOS-2 cells (stimulated by 
mineralization media including β-glycerophosphate and 
ascorbic acid) was detected and quantitated by fluores-
cent staining (Fig.  4). The highest amount of HA deposi-
tion was observed after the first 5 days of cultivation, and 
longer cultivation time did not further increase the amount 
of HA deposition (Fig. 4A). The inhibitory effect of fully 
phosphorylated OPN and OPN dephosphorylated with 
TRAP and BALP was studied by measuring the amount of 
HA produced after initiation of mineralization. Cells grown 
only with mineralization medium, without OPN, were 
defined as controls and considered to be fully mineralized 
and set to 100%. Fully phosphorylated OPN decreased the 
amount of produced HA by 67% (Fig. 5). Dephosphoryla-
tion of OPN with TRAP gradually decreased the inhibitory 
Fig. 2  A Differences between TRAP, BALP, and IALP regarding 
the dephosphorylation efficiency on OPN. These results demonstrate 
the amount of liberated free phosphate cleaved off from OPN after 
24-h incubation with 5 mU of TRAP, BALP, and IALP. B Maximum 
amount of phosphate liberated from the OPN molecule after 24 h of 
incubation with different concentrations of BALP (filled square) and 
IALP (open square). Statistical comparisons were made between the 
maximum values of liberated free phosphate for each enzyme after 
24-h incubation of each enzyme. Results are presented as mean ± SD 
of three independent experiments. ** P < 0.01, *** P < 0.001
Fig. 3  Dephosphorylation of OPN with TRAP, BALP, and IALP 
with respect to liberated free phosphate per mol OPN calculated per 
hour and mU enzyme. * P < 0.05, ** P < 0.01
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effect of OPN the more phosphate that was cleaved off. 
Fully dephosphorylated OPN (i.e., −28 phosphates by 
TRAP) had no inhibitory effect on the mineralization pro-
cess in this in vitro model (Fig. 5A). BALP, removing two 
phosphates per mol OPN, decreased the inhibitory capac-
ity of OPN by approximately one-third to the same level 
as observed when removing five phosphates. Removing 
ten phosphates reduced the inhibitory capacity in compari-
son with OPN with only two phosphates being removed 
(Fig. 5B).
Fig. 4  A Osteoblast-like SaOS-2 cells cultured for 3, 5, 7, 10, and 
21 days after initiation of mineralization (without OPN). Cells were 
stained with the OsteoImage Mineralization Assay, which specifi-
cally detects the HA portion of bone-like nodules deposited by cells. 
Fluorescence was measured in relative fluorescence units (RFU) and 
is proportional to the amount of HA present in the culture. Results are 
presented as mean ± SD of eight samples. B Image of cells cultured 
for 10 days without mineralization medium. C Image of cells cultured 
for 10 days with mineralization medium (without OPN)
Fig. 5  Amount of mineralization in osteoblast-like SaOS-2 cells 
5  days after initiation of mineralization. Cells grown with minerali-
zation medium but without OPN were defined as controls and con-
sidered to be fully mineralized, and set to 100% relative fluorescence 
units (RFU). The other bars are expressed as percentages of 100% 
RFU. +OPN indicates the addition of OPN (fully phosphorylated), 
and −2P, −5P, −10P, and −28P indicate the number of phosphates 
cleaved off (dephosphorylated OPN). OPN, fully phosphorylated and 
dephosphorylated, was added at a final concentration of 0.1 µg/mL. 
Results are presented as mean ± SD of three independent experiments 
with eight samples in each experiment. A OPN fully phosphorylated 
and dephosphorylated by TRAP. B OPN fully phosphorylated and 
dephosphorylated by BALP. *  P < 0.05, **  P < 0.01, ***  P < 0.005, 
ns not significant
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Discussion
Besides being highly expressed in osteoclasts, TRAP is 
also expressed in osteoblasts and osteocytes [18, 19]; how-
ever, the potential capacity for TRAP as a regulator of 
mineralization, with or without a functional interplay with 
BALP, has not been addressed. The present work demon-
strates that TRAP can completely dephosphorylate the min-
eralization inhibitor OPN (–28 phosphates), whereas BALP 
and IALP dephosphorylate OPN by 36% (–10 phosphates) 
and 71% (–20 phosphates), respectively. In a previous study 
by Ek-Rylander et  al. [33], no dephosphorylation of OPN 
was observed with TNALP from bovine kidney. However, 
in the present study, using dose–response and time course 
assays, we observed a significant OPN phosphatase activ-
ity of TNALP, purified from bone, although at a lesser 
extent in comparison with TRAP. TRAP also displayed a 
much higher phosphatase activity towards PPi and pNPP in 
comparison with BALP, whereas the activity of TRAP and 
BALP towards PLP was similar. To our knowledge, there 
is only one previous study that has investigated the kinetic 
properties of TRAP towards PPi, but none regarding PLP. 
Lam et  al. [34] reported that TRAP has similar reactivity 
towards pNPP and PPi. Both BALP and TRAP are pre-
sent in osteoblasts and exhibit significant activity against 
the mineralization inhibitor PPi, which indicates that both 
these phosphatases could potentially participate in the reg-
ulation of the intricate process of mineralization.
Unlike BALP, TRAP is expressed in osteocytes [19, 
35]. There are data suggesting that osteocytes remodel its 
lacunae and canaliculae [36, 37], which involves similar 
mechanisms that osteoclasts use for resorbing bone (i.e., 
acidification, demineralization, and collagen degradation). 
The subsequent formation process in the osteocyte lacuna 
remains elusive; however, we suggest that this process 
could be mediated by TRAP, instead of BALP, in control-
ling the inhibitory effect of PPi and/or OPN.
OPN is expressed in several tissues, including bone 
matrix, and is involved in numerous biological processes. 
The degree of phosphorylation of OPN is of significant 
importance for its functional properties. For example, 
dephosphorylation of OPN by TRAP influences the migra-
tion and attachment of osteoclasts [14], and phosphorylated 
OPN peptides have previously been shown to inhibit HA 
formation in vitro, while the same peptides without phos-
phate lacked inhibitory effect on mineralization [38]. The 
current study shows that the inhibitory effect of OPN on 
mineralization was significantly influenced by the degree 
of phosphorylation in cultures with osteoblast-like cells. 
TRAP dephosphorylated OPN completely, which totally 
eliminated the inhibitory action of OPN on mineraliza-
tion, while BALP only removed 36% of the phosphates, 
which resulted in a partial restoration of mineralization. 
In contrast, Hunter et al. [39] were able to remove 84% of 
bound phosphate from OPN with the use of ALP coupled 
to agarose beads. The source of ALP immobilized on these 
agarose beads is commonly calf IALP in very high concen-
trations because IALP is a rather inexpensive and wide-
spread phosphatase. In a cell-free system, this approach of 
dephosphorylation reduced the de novo formation of HA by 
more than 40-fold [39]. The same method with IALP-cou-
pled agarose beads to dephosphorylate OPN was applied by 
Jono et al. [32], who demonstrated that bacterium-derived 
recombinant OPN (with 20 phosphates) phosphorylated 
by casein kinase II inhibited human smooth muscle cell 
culture calcification, while dephosphorylation of the same 
OPN did not. In this study, we demonstrate that BALP and 
IALP differ significantly in their dephosphorylating prop-
erties. Hence, the results and conclusions from investigat-
ing both skeletal mineralization and vascular calcification, 
applying IALP to dephosphorylate phosphoproteins, e.g., 
OPN, should be interpreted with caution because of the 
delineated differences between BALP and IALP.
Whereas the majority of reports have described 
Spp1−/− mice (a.k.a., OPN knockout mice) as being 
largely normal, Fourier transform infrared imaging spec-
troscopy analysis has been used to document mineraliza-
tion abnormalities in the Spp1−/− mice and to detect more 
mineral in the mutant animals than in wild-type controls 
[6, 40]. Ten-day-old Spp1−/− mice have more mineralized 
osteoid than wild-type controls, and in  vitro cultures of 
calvarial osteoblasts produced more von Kossa-positive 
nodules over the course of a 21-day differentiation assay 
than wild-type controls [41]. The degree of severity of 
the hypermineralization phenotype in Spp1−/− mice is 
however very mild, a fact that we have attributed to the 
very high levels of extracellular PPi in these mice. At 
ten days of age, Spp1−/− mice have extracellular PPi lev-
els even higher than those observed in the Alpl−/− mice, 
where extracellular PPi excess promotes rickets/osteo-
malacia [25]. We surmise that the increased levels of 
PPi compensate for the lack of OPN limiting what would 
otherwise be excessive mineralization due to the lack of 
OPN.
Complete removal of all phosphates bound to OPN is 
not possible with IALP or BALP but with TRAP. TRAP 
could, therefore, be a physiological regulator of OPNs’ 
inhibitory action on mineralization. The partial dephos-
phorylation of OPN achieved by BALP also reduces the 
inhibitory action of OPN and influences the mineralization. 
BALP is present at the site of mineralization and these data 
confirm that BALP also acts as a regulator of OPN [42]. 
Intriguingly, the present data suggest that several phospho-
rylations are implicated in the inhibitory action of OPN. 
Some of these phosphorylations, which are rapidly lib-
erated by either BALP or TRAP, seem to be controlling 
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approximately 40–50% of the inhibitory effect, while the 
remaining inhibition is among the last 18 phosphorylations 
only liberated by TRAP. This indicates that there are quali-
tative differences in the action of BALP and TRAP, which 
may have consequences for their functional roles in regu-
lating mineralization. In addition, the different efficiencies 
in phosphate removal from OPN by TRAP and BALP may 
partly explain the observed heterogeneity in OPN phospho-
rylation in bone extracts [11, 43]. There are data indicating 
that the bone tissue of TRAP knockout mice (Acp5−/−) is 
hypermineralized, as well as a disturbed mineralization in 
the growth plate [44]. However, these findings seem to be 
secondary to the reduced bone-resorptive activity of osteo-
clasts leading to a mild osteopetrotic phenotype. Moreover, 
inactivating mutations in the ACP5 gene (encoding TRAP) 
cause the rare recessive disorder spondyloenchondrodys-
plasia, which includes autoimmunity disease features, e.g., 
systemic lupus erythematosus [45], associated with dis-
turbed bone development and short stature probably medi-
ated by impaired dephosphorylation of OPN [46, 47].
Besides partially dephosphorylating OPN, BALP is 
also an important mineralization promoter via its ability 
to hydrolyze the mineralization inhibitor PPi, thereby fine-
tuning the local extracellular ratio between PPi and free 
phosphate pivotal for optimal mineralization conditions [3]. 
Considering the results from the current study, the ques-
tion remains if BALP and TRAP co-regulate the inhibi-
tory properties of OPN during mineralization. Narisawa 
et al. [42] found that OPN in long bones from Alpl−/− mice 
is hyperphosphorylated in comparison with WT (Alpl+/+) 
control mice, while the degree of phosphorylation is 
decreased in OPN from Alpl−/− mice that overexpress 
human TNALP transgene in bone (i.e., ColTg; Alpl−/−), 
which suggests that mouse TNALP and human TNALP 
dephosphorylate OPN in bone. Since BALP and TRAP are 
not co-expressed to a large extent in the same cells, or com-
partments in bone, it seems plausible that these enzymes 
mainly exert functions that are independent of each other.
It should be noted that the microenvironment, especially 
the pH at the site of action of these phosphatases, may 
considerably influence their action on the mineralization 
inhibitors PPi and OPN. Whereas BALP is active at basic 
pH, TRAP exerts optimal activity at acidic pH and show 
low activity at neutral and basic pH. It is possible that the 
action of TRAP on OPN and PPi may facilitate mineraliza-
tion of bone remodeling units that occurs during the for-
mation phase after the osteoclast has excavated the bone at 
acidic pH. It has been shown that TRAP remains associ-
ated to the resorbed bone after its secretion to the resorp-
tion pocket [22, 48], and might there modify the surface 
by, e.g., dephosphorylation of OPN to permit and facilitate 
subsequent bone formation in the resorption pit.
The current study has a number of strengths, includ-
ing the use of BALP extracted from human bone tissue. 
Previous studies investigating the inhibitory properties of 
OPN have applied excessive amounts of IALP to dephos-
phorylate OPN. Needless to say, IALP is not present 
at the mineralization site, but more notably it is a differ-
ent isozyme than BALP (TNALP expressed in bone) with 
approximately only 50% sequence identity [24]. Results 
from the present study demonstrate that BALP and IALP 
differ significantly in their dephosphorylating properties. 
In addition, this study presents the first data on the inhibi-
tory effect of OPN dephosphorylated by TRAP on in vitro 
mineralization of human osteoblast-like cells. However, 
this study also possesses limitations that warrant considera-
tion when interpreting the data. The degree of phosphoryla-
tion for OPN varies when isolated from different sources 
and species. Gericke et al. [49] investigated various forms 
of OPN (i.e., rat bone OPN, recombinant OPN, and bovine 
milk OPN), including different degrees of phosphorylation, 
and demonstrated the importance of phosphorylation as a 
pivotal factor in regulating OPN-mediated mineralization. 
We used bovine milk OPN with 28 phosphorylation sites 
in the current study, which inhibited the mineralization by 
approximately 70%.
To summarize, our results provide novel insight how 
both BALP and TRAP can alleviate the inhibitory effect 
of bovine milk OPN on mineralization. The current study 
indicates that both these phosphatases are important regu-
lators of mineralization but with different roles in the min-
eralization process. The different roles may depend on site 
specificity, that is, typical osteoblast-derived mineralization 
by BALP, or mineralization facilitated by TRAP in the oste-
ocyte lacunae and resorption pit to dephosphorylate newly 
released OPN which could inhibit de novo bone formation. 
This study presents evidence that TRAP displays enzymatic 
activity towards the endogenous substrates for BALP, i.e., 
PPi and PLP (in addition to OPN). BALP can dephospho-
rylate OPN partially and influence its inhibitory effect on 
mineralization, whereas TRAP can dephosphorylate OPN 
completely and eliminate the inhibitory effect of OPN. 
Further studies are needed to elucidate the possible physi-
ological relevance of TRAP in the osteoblastic lineage, and 
the mechanistic interplay between BALP, TRAP, OPN, and 
PPi, during the intricate process of mineralization.
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